Stuttgart - Delayed Quote EUR

Sanofi SA (SNW.SG)

92.52

-1.37

(-1.46%)

At close: 9:45:05 PM GMT+2

Swiss Agree to Tariff Negotiations With Trump Administration

(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergTrump Gives New York ‘One Last Chance’ to End Congestion FeeWhy Car YouTuber Matt Farah Is Fighting for Walkable CitiesBackyard Micro-Flats Aim to Ease South Africa’s Housing CrisisThe Racial Wealth Gap Is Not Just About MoneyTo Fuel Affordable Housing, This Innovation Fund Targets Predevelopment CostsSwitzerland said it’s one of 15 countries that will get “somewhat preferential treat

Bloomberg 14 hours ago

SNY

SNYNF
0.00%
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed

Roche beat first-quarter sales expectations Thursday, while Sanofi's sales report came in mixed. Shares were muted in premarket trades.

Investor's Business Daily yesterday

SNY

SNYNF
0.00%
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug

The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.

The Wall Street Journal yesterday

SNY

SNYNF
0.00%
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER1 and business EPS2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIODupixent sales were €3.5 billion, up 20.3%Vaccines sales were €1.3 billion, up 11.4%, driven by favorable Beyfortus phasingResearch and Development expenses reached €1.8 billion, up 6.9%Selling, general and administrative expenses were €2.2 billion, up 3.8%Business EPS was €1.79, up 1

GlobeNewswire yesterday

SNY

SNYNF
0.00%
Why vaccine makers aren't worried about Trump administration cuts

Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

Yahoo Finance 2 days ago

MRK

SNY

SNYNF
0.00%
Regeneron, Sanofi announce FDA approval of Dupixent for CSU

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite histamine-1 antihistamine treatment. “Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over ten years, with pivotal trials demonstrating its ability to help patients significantly reduce the hallmark

TipRanks 6 days ago

SNY

SNYNF
0.00%
REGN
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced

GlobeNewswire 7 days ago

SNY

SNYNF
0.00%
REGN
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved Paris and Tarrytown, NY,

GlobeNewswire 7 days ago

SNY

SNYNF
0.00%
Stocks to watch this week: Tesla, Alphabet, Intel, Boeing and Unilever

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK 7 days ago

DELHY

DLVHF

IHCPF
Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement

Sanofi, a leader in diabetes care, welcomes author, entrepreneur, and mom Chrissy Teigen as its new celebrity spokesperson for the Screen For Type 1 movement. The partnership, announced on T1D Day, comes as the Screen For Type 1 movement strives to expand diabetes education nationwide, raising awareness of the benefits of early risk detection.

PR Newswire 10 days ago

SNY

SNYNF
0.00%
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthmaItepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis; phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026 Paris, April 15, 2025. Sanofi today shared new progress from its mid- to late-stage r

GlobeNewswire 10 days ago

SNY

SNYNF
0.00%
Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’

(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.President Donald Trump said his long-promised tariffs on pharmaceutical drugs will be coming soon, the latest signal that he plans to press ahead with more sectoral tariffs despite market fallout from his global levies.“We are going to be announcing very shortly a major tariff on pharmaceuticals,” Trump said Tuesday at a fundraising gala for House Republicans, without providing details on the planned levy.“O

Bloomberg 16 days ago

BMY

CELG-RT

PFE
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosisTolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MSTolebrutinib is being evaluated under priorit

GlobeNewswire 17 days ago

SNY

SNYNF
0.00%
Tariffs Stoke Fears That Hung Debt Will Return

(Bloomberg) -- Deals in leveraged finance have stalled, and markets have been upended, raising the possibility that banks might once again get stuck with debt they’ve committed for acquisitions.Most Read from BloombergHousing Agency Aims to Relocate Its DC HeadquartersBoston Mayor Wu Embraces Trump Resistance as Campaign Heats UpThis Skinny Mexico City Tower Is Just 14 Feet Wide on One SideThe Irish Hot Press Is the Low-Tech Laundry Trick the World NeedsWhat Would ‘Transportation Abundance’ Look

Bloomberg 20 days ago

C

WW

SNY
Sanofi: Information concerning the total number of voting rights and shares - February 2025

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,467,152,142Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis

GlobeNewswire 22 days ago

SNY

SNYNF
0.00%
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related diseaseRilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton’s tyrosine kina

GlobeNewswire 22 days ago

SNY

SNYNF
0.00%
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few as six injections a year via a prefilled pen or vial and syringeUnique mechanism helps reduce the frequency of bleeding episodes for people with hemophilia Paris, March 28, 2025. The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-low

GlobeNewswire 28 days ago

SNY

SNYNF
0.00%
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophilsApproval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammation Paris and Tarrytown, NY, March 28, 2025. The Ministry of Health, Labour and Welfare in Japan

GlobeNewswire 28 days ago

SNY

SNYNF
0.00%
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammation TARRYTOWN, N.Y. and PARIS, March 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and

GlobeNewswire 28 days ago

REGN

SNY

SNYNF
0.00%
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infertilityA phase 1/2 clinical study evaluating the immunogenicity and safety of the vaccine candidate is due to start in coming days Paris, March 26, 2025. The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection

GlobeNewswire 30 days ago

SNY

SNYNF
0.00%

Performance Overview

Return	SNW.SG	CAC 40 (^FCHI)
YTD	-1.17%	+2.11%
1-Year	+4.95%	-5.99%
3-Year	+2.17%	+16.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sanofi SA (SNW.SG)

Swiss Agree to Tariff Negotiations With Trump Administration

Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

Why vaccine makers aren't worried about Trump administration cuts

Regeneron, Sanofi announce FDA approval of Dupixent for CSU

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Stocks to watch this week: Tesla, Alphabet, Intel, Boeing and Unilever

Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Tariffs Stoke Fears That Hung Debt Will Return

Sanofi: Information concerning the total number of voting rights and shares - February 2025

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

Performance Overview